{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:47:14Z","timestamp":1792673234692,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HI12C0003"],"award-info":[{"award-number":["HI12C0003"]}]}],"content-domain":{"domain":["journalofpsychiatricresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jpsychires.2015.02.017","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T17:18:49Z","timestamp":1426094329000},"page":"88-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"64","author":[{"given":"Chi-Un","family":"Pae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin A.","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praksh S.","family":"Masand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2015.02.017_bib1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4088\/JCP.09m05328gry","article-title":"Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"71","author":"Alegria","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/030079907X182202","article-title":"Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials","volume":"23","author":"Allgulander","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A\u00a0double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.euroneuro.2012.07.018","article-title":"On assessing potential efficacy for vortioxetine in generalized anxiety disorder","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S1461145710001434","article-title":"Evidence-based pharmacological treatment of generalized anxiety disorder","volume":"14","author":"Baldwin","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A\u00a0randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/YIC.0b013e3283530ad7","article-title":"Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder","volume":"27","author":"Baldwin","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Care WTFoMDiP, Wfsbp task force on anxiety disorders OCD, & Ptsd. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib10","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12888-014-0276-x","article-title":"Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials","volume":"14","author":"Berhan","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2012.07.012","article-title":"Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial","volume":"22","author":"Bidzan","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1037\/1082-989X.8.3.243","article-title":"How meta-analysis increases statistical power","volume":"8","author":"Cohn","year":"2003","journal-title":"Psychol Methods"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.mcna.2014.06.003","article-title":"Anxiety disorders in primary care","volume":"98","author":"Combs","year":"2014","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib16","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0006-3223(98)00285-6","article-title":"Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives","volume":"44","author":"Connor","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/17425255.2014.904286","article-title":"Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder","volume":"10","author":"Dubovsky","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ncprheum0732","article-title":"Primer: strengths and weaknesses of meta-analysis","volume":"4","author":"Finckh","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00213-014-3633-z","article-title":"The efficacy and safety of 5 mg\/d Vortioxetine compared to placebo for major depressive disorder: a meta-analysis","volume":"232","author":"Fu","year":"2015","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neuropharm.2013.05.014","article-title":"Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice","volume":"73","author":"Guilloux","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4306\/pi.2015.12.1.1","article-title":"Pain and depression: a neurobiological perspective of their relationship","volume":"12","author":"Han","year":"2015","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jpsychires.2014.05.003","article-title":"The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder","volume":"56","author":"Han","year":"2014","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0269881107076996","article-title":"An effect-size analysis of pharmacologic treatments for generalized anxiety disorder","volume":"21","author":"Hidalgo","year":"2007","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A\u00a0randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.jpsychires.2015.02.017_bib24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145702002912","article-title":"Are placebo controls necessary to test new antidepressants and anxiolytics?","volume":"5","author":"Khan","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.10m06191","article-title":"Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications","volume":"72","author":"Khin","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib28","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.11r07539","article-title":"Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration","volume":"73","author":"Khin","year":"2012","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1185\/03007995.2012.761600","article-title":"A\u00a0randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder","volume":"29","author":"Mahableshwarkar","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ijcp.12328","article-title":"A\u00a0randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder","volume":"68","author":"Mahableshwarkar","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hup.2371","article-title":"A\u00a0randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder","volume":"29","author":"Mahableshwarkar","year":"2014","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib32","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1098\/rstb.2012.0212","article-title":"Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression","volume":"367","author":"Massart","year":"2012","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib33","first-page":"86","article-title":"Imaging the serotonin transporter during major depressive disorder and antidepressant treatment","volume":"32","author":"Meyer","year":"2007","journal-title":"J\u00a0Psychiatry Neurosci"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000155821.74832.f9","article-title":"A\u00a0meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder","volume":"25","author":"Mitte","year":"2005","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib35","series-title":"Clinical guidelines for the management of anxiety: Management of anxiety (panic disorder, with or without agor aphobia, and generalised anxiety disorder) in adults in primary, secondary and community care","author":"National Institute for Health and Care Excellence","year":"2004"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib48","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature09282","article-title":"Amygdalar and hippocampal substrates of anxious temperament differ in their heritability","volume":"466","author":"Oler","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4306\/pi.2014.11.4.371","article-title":"A meta-analysis comparing open-label versus placebo-controlled clinical trials for aripiprazole augmentation in the treatment of major depressive disorder: lessons and promises","volume":"11","author":"Pae","year":"2014","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib37","doi-asserted-by":"crossref","DOI":"10.1503\/jpn.140120","article-title":"Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder","author":"Pae","year":"2015","journal-title":"J\u00a0Psychiatr Neurosci"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuropharm.2011.09.003","article-title":"The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building?","volume":"62","author":"Petrik","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib38","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States","volume":"22","author":"Rothschild","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.jpsychires.2015.02.017_bib40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.s.7002.03","article-title":"Neurobiology of generalized anxiety disorder","volume":"70","author":"Stein","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib41","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.euroneuro.2013.01.002","article-title":"5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects","volume":"23","author":"Stenkrona","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4088\/JCP.09m05725blu","article-title":"Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach","volume":"72","author":"Tedeschini","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib43","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/da.22203","article-title":"Anxiety disorders are independently associated with suicide ideation and attempts: propensity score matching in two epidemiological samples","volume":"30","author":"Thibodeau","year":"2013","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib44","article-title":"Impairment and functioning in a sample of primary care patients with generalized anxiety disorder: results from the primary care anxiety project","volume":"12","author":"Weisberg","year":"2010","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.02.017_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00004850-200015060-00002","article-title":"Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey","volume":"15","author":"Wittchen","year":"2000","journal-title":"Int Clin Psychopharmacol"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395615000618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395615000618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T14:20:59Z","timestamp":1537798859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395615000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":49,"alternative-id":["S0022395615000618"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2015.02.017","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2015.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}